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Abstract
Background: Globally, the burden of diabetes mellitus has increased to epidemic proportions. Estimates from the
International Diabetes Federation predict that the greatest future increase in the prevalence of diabetes mellitus will
occur in Africa.
Methods: This article reviews literature on the manifestation of diabetes in adult patients in sub-Saharan Africa
highlighting the distinct phenotypes, plausible explanations for this unique manifestation and the clinical
significance of comprehensively defining and understanding the African diabetes phenotype.
Results: There are few studies on the manifestation or phenotype of diabetes in Africa. The limited data available
suggests that, compared to the Western world, the majority of patients with diabetes in Africa are young and relatively
lean in body size. In addition, hyperglycaemia in most cases is characterised by a significantly blunted acute first phase
of insulin secretion in response to an oral or intravenous glucose load and pancreatic beta cell secretory dysfunction,
rather than peripheral insulin resistance predominates. Genetic and environmental factors like chronic infections/
inflammation, early life malnutrition and epigenetic modifications are thought to contribute to these distinct
differences in manifestation.
Conclusions: While published data is limited, there appears to be distinct phenotypes of diabetes in sub-Saharan
Africa. Large and more detailed studies are needed especially among newly diagnosed patients to fully characterize
diabetes in this region. This will further improve the understanding of manifestation of diabetes and guide the
formulation of optimal therapeutic approaches and preventive strategies of the condition on the continent.
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Background
Burden of diabetes: Globally and in Africa
Globally, the prevalence of diabetes mellitus (DM) has
reached epidemic levels especially in low and middle in-
come countries. According to the 2017 International
Diabetes Federation (IDF) estimates, about 425 million
adults have DM. This figure is projected to increase to
629 million adults by 2045, which is a 48% increase [1].
Africa is estimated to have 15.9 million adults living
with DM which is a regional prevalence of 3.1%. The
African continent has the greatest proportion of people
with undiagnosed DM and global projections show that
it will experience the greatest future increase in the bur-
den of DM of about 156% by 2045 [1].
This growing burden of DM globally and in Africa has
also been demonstrated by the pooled analysis of 751
population based studies performed in 146 countries
from 1980 to 2014 by the Non-Communicable Diseases
Risk Factor Collaboration (NCD-RisC) [2]. The global
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age-standardized diabetes prevalence increased from 4·3%
(95% CI 2.4–7.0) in 1980 to 9·0% (95% CI 7.2–11.1) in
2014 in men and from 5% (95% CI 2.9–7.9) to 7.9% (95%
CI 6.4–9.7) in women and worldwide, the number of
adults with diabetes increased from 108 million in 1980 to
422 million in 2014. North Africa was one of the regions
with the highest age standardized diabetes prevalence [2].
According to findings from the NCD-RisC Africa work-
ing group that analysed pooled data of 76 surveys
(182,000 participants) from 32 countries performed be-
tween 1980 and 2014, the age standardized prevalence of
DM increased from 3.4% (1.5–6.3) to 8.5% (6.5–10.8) in
men, and from 4.1% (2.0–7.5) to 8.9% (6.9–11.2) in
women [3]. The burden of DM was mostly higher in the
Northern and Southern regions and a positive association
was observed between mean body mass index (BMI) and
diabetes prevalence in both sexes during that period [3].
The increasing dual burden of non-communicable dis-
eases (NCD) like DM and communicable diseases such as
HIV and tuberculosis puts a significant economic strain
on the existing resource constrained health systems in
sub-Saharan Africa (SSA). It also has huge economic im-
plications for patients and their immediate families. It will
therefore be crucial to fully understand how DM mani-
fests in Africa to formulate and implement effective tar-
geted preventive strategies and optimal management to
reduce diabetes related morbidity and mortality.
Methods
We searched PubMed, Google scholar, Scopus and Afri-
can Journal Online databases for any published review ar-
ticles, case reports and original research articles,
regardless of year of publication that reported information
about the manifestation of diabetes in adult patients in
SSA emphasising mainly the reported distinct phenotypes.
References of the identified publications were searched for
more research articles to include in this narrative review.
The search terms used were: “manifestation of dia-
betes” OR “diabetes phenotypes” OR “presentation of
diabetes” OR “characteristics of diabetes” OR “atypical
diabetes” AND “Africa” OR “sub-Saharan Africa”.
We excluded research articles published in languages
other than English and whose full texts were not accessible.
A total of 16 original articles, review articles and case
reports containing information about the distinct dia-
betes phenotype in SSA were included in this narrative
review [4–19].
Results
Manifestation of diabetes in sub Saharan Africa:
Metabolic and immunologic characterization and atypical
forms of diabetes
Both type 1 DM (T1DM) and type 2 DM (T2DM) are het-
erogeneous diseases that are characterized by a constellation
of metabolic disorders and vary considerably in clinical pres-
entation and disease progression [20].
A number of reports show that compared to
high-income countries, the majority of adult patients di-
agnosed with DM in sub-Saharan Africa (SSA) are of
median age of < 50 years (signifying early disease onset),
lean body size (have low or normal BMI) and pancreatic
beta cell secretory dysfunction characterised by a signifi-
cantly blunted acute first phase of insulin secretion in
response to an intravenous or oral glucose load predom-
inates rather than peripheral insulin resistance [4–12].
This is in contrast with evidence reported from the
Western world where DM appears to develop later in
life (> 50 years), is common among overweight or mor-
bidly obese individuals and increased IR, hyperinsulinae-
mia with progressive pancreatic beta cell secretory
dysfunction occurring later in the course of the disease,
as the hallmarks of DM [21, 22].
The observed predominant pancreatic beta cell
secretory dysfunction might explain why DM in Africa is
commonly associated with low BMI, keto-acidosis, rapid
decline in fasting plasma C-peptide concentrations and
early onset of secondary oral agent failure following
diagnosis. The reasons for the above discussed differ-
ences in manifestation or diabetes phenotype are un-
clear, but may reflect genetic diversity and unique
environmental factors in Africa.
Currently, there is a paradigm shift in the classification
of DM from the definition based on need of insulin ther-
apy to achieve euglycaemia and age of disease onset or
diagnosis to a definition based on an in-depth definition
of the underlying aetiopathogenetic mechanisms of
hyperglycaemia [23]. This underscores the need to com-
prehensively describe and understand the phenotype of
diabetes in SSA. This would help in guiding optimal and
individualised management of patients with DM in clin-
ical practice.
Clinical and biochemical characterisation of diabetes in
adult diabetic populations in sub-Saharan Africa
There have been very few published studies that have
thoroughly investigated the clinical, metabolic and im-
munologic profile of African patients with DM. Despite
this limitation, the available studies performed to dem-
onstrate the distinct diabetes phenotype in SSA offer
useful insights into the clinical and biochemical profile
particularly with regard to the frequency of insulin re-
sistance, beta cell secretory dysfunction and presence of
pancreatic auto-immunity.
In one cross sectional study of 105 adult patients with
DM conducted in the Tigray region of Northern
Ethiopia (a semi-arid region), the mean age and median
BMI was 41 ± 16 years and 20.6 (18.5–23.9) kg/m2 re-
spectively [5], highlighting a young age at diagnosis and
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lean body size. Insulin deficiency expressed as C-peptide
negative status on examination was reported in 43% of
the patients with 28 and 3.8% of patients positive for
glutamic acid decarboxylase antibodies (GADA) and islet
antigen 2 antibody (IA-2A) tests respectively. About 38
(36%) patients had immunological and C-peptide charac-
teristics that were not consistent with the classical
T1DM and T2DM phenotypes, despite having clinical
features similar to patients with T1DM (similar median
age at diagnosis, glycated haemoglobin level and BMI).
GADA positivity and C-peptide negativity in this
sub-group was confirmed in 29 and 71% respectively [5].
This underscores the presence of diabetes phenotypes in
SSA that may not fit the conventional classification of
DM.
In another case control study that assessed the degree
of basal insulin resistance (IR) and insulin secretion (IS)
using the homeostatic model assessment (HOMA)
among 146 patients with T2DM and 33 healthy controls
performed in an urban hospital in Nigeria, IR and re-
duced IS prevalence among the T2DM patients was 95.5
and 74.7% respectively [7], demonstrating a high dual
burden of IR and pancreatic beta cell secretory dysfunc-
tion. However, approximately 85% of the patients in this
study were obese, which could explain the higher preva-
lence of IR. The independent predictors of IR in this
study were age at diagnosis, waist circumference and
duration of DM and those for reduced IS, duration of
DM and waist circumference [7]. While the duration of
DM in these patients was not reported, the prevalence
of beta cell secretory dysfunction reported could prob-
ably have arisen as a result of beta cell exhaustion occur-
ring as the disease progresses.
Another similar small study conducted in Nigeria
comparing 40 patients with T2DM to 36 healthy con-
trols reported an IR (defined as HOMA1-IR values > 1)
prevalence of 87.5% in patients and 27.8% in the con-
trols [8]. When a HOMA1-IR score ≥ 2 was used, IR was
prevalent in 40% of the patients and 19.4% of the
controls.
Two studies reported from Ghana reported severe
pancreatic beta cell secretory dysfunction among a small
adult population with DM [9, 10]. Amoah A et al. in
their study that compared 15 healthy controls without
family history of DM (group 1) with 11 healthy controls
with first degree family history of DM (group 2) and 10
patients with T2DM (group 3) found that group 3 had
severely blunted acute phases of insulin secretion follow-
ing an intravenous glucose load as measured by the ab-
solute and incremental area under the curve [10]. The
mean acute first phase insulin secreted in the 1st, 2nd
and 3rd group was 122 ± 75, 320 ± 11.7 and 7.8 ± 5.7
mU/l x minutes respectively with insulin sensitivity
index lowest in the diabetic group [10].
Plausible explanations for recognised distinct
manifestation of diabetes in SSA
The African continent harbors the highest genetic het-
erogeneity. It is also unique because it continues to have
a high burden of infectious diseases and other challenges
like famine, civil strife and malnutrition. These expo-
sures might modulate the pathogenesis and clinical
course of NCD like DM, as summarized in Fig. 1.
There are clearly defined potential causes of the well
documented distinct diabetes phenotype in SSA, while
the others are less well investigated.
Chronic infections and chronic pro-inflammatory state
Chronic infections notably HIV and tuberculosis (TB) that
are highly endemic in SSA provoke a state of chronic in-
flammation which may play an important role in the
pathogenesis of DM and other NCD, with proposed
mechanisms including increased oxidative stress, vascular
endothelial dysfunction and DNA damage [24]. This in-
flammatory cascade can lead to premature aging of key
homeostatic organs like the pancreas and progressive de-
cline of physiological functions. This eventually results
into early onset of cardio-metabolic disorders like DM.
The pro-inflammatory state associated with infections
like TB is also linked to increased release of counter
regulatory stress hormones like cortisol and epinephrine
which cause reactionary hyperglycaemia due to their an-
tagonistic effects to insulin [25, 26]. The consequent re-
actionary hyperglycaemia can persist after TB treatment.
The immune activation associated with HIV infection is
also associated with a state of peripheral insulin resist-
ance and reduced insulin secretion, hence increasing the
risk of DM and metabolic syndrome at an early age [27].
Infection induced hypersensitivity reaction/autoimmunity
Exaggerated immune responses (hypersensitivity reac-
tion) and molecular mimicry as seen with some chronic
infections have been implicated in pathogenesis of auto-
immune conditions with subsequent organ dysfunction
occurring especially in genetically predisposed individ-
uals [28–30]. The underlying mechanisms explaining the
hypersensitivity and autoimmunity induced by chronic
infections include presence of antigenic mimicry,
neo-antigen formation and immune dysregulation of the
host [28].
Autoimmune destruction of pancreatic beta cells in-
duced by enteroviruses like coxsackie B virus, rubella
virus, rotavirus, flavivirus, herpes virus, rhinovirus and
retrovirus have long been implicated as infectious aetiol-
ogies of T1DM [29–33].
Direct organ damage by the pathogen
Direct pancreatic beta cell damage with subsequent
endocrine dysfunction has also been highlighted as a
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potential mechanism of how infections can cause DM,
impaired glucose tolerance at an early age and pancre-
atic beta cell secretory dysfunction. Tuberculous de-
struction of the beta and alpha cells of the pancreas, for
example is often associated with brittle DM which is fre-
quently characterised by labile blood glucose levels [25].
A close association has also been described between
human herpes virus type 8, a virus endemic in the tro-
pics responsible for causing Kaposi sarcoma and an
atypical form of DM, ketosis prone diabetes (KPD) [13].
It is thought that it causes endoplasmic reticulum stress
and direct destruction of the pancreatic beta cells which
results in reduced insulin secretion [13].
Effect of treatment of the infections
The HIV epidemic in SSA, coupled with increased
access to antiretroviral therapy (ART) and longer life ex-
pectancy of HIV infected patients have been associated
with development of multiple metabolic derangements
[34] and could also partly explain the distinct pheno-
types of diabetes in SSA.
Anti-retroviral therapy notably efavirenz and protease
inhibitors have been shown to increase the risk of dys-
glycaemia [35–37]. Unequivocal evidence shows that
these classes of ART cause mitochondrial dysfunction,
significant changes in body fat distribution (increased
central adiposity and peripheral lipoatrophy) and reduce
cellular uptake of glucose by impairing the activity of the
glucose transporter-4 [27, 36–39].
Rifampicin, one of the potent anti TB drugs is also as-
sociated with a transient hyperglycaemia that may persist
during and after treatment because of its effect of aug-
menting intestinal glucose absorption [25].
Chronic prenatal and postnatal malnutrition (thrifty
phenotype hypothesis)
Chronic prenatal and postnatal malnutrition frequently
seen in most parts of SSA especially in the rural areas is
a recognised precursor for DM and other NCD and
could also explain the distinct diabetes phenotypes seen
in SSA. The link between perinatal malnutrition during
periods of famine and increased odds of developing DM
Fig. 1 Plausible explanations for the distinct diabetes phenotype in sub Saharan Africa. KPD: Ketosis Prone Diabetes, FCPD: Fibrocalculous
pancreatic diabetes
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later in life has been demonstrated in studies reported
from Ukraine [40] and Ethiopia [41].
The thrifty phenotype hypothesis which was described
several decades ago by Nicholas Hales and David Barker
expounds on the link between chronic perinatal malnu-
trition which manifests as low birth weight and failure
to thrive with subsequent development of NCD like
T2DM in adulthood [42]. One hypothesis to explain the
future development of T2DM in patients with a history
of early life malnutrition is possibly impaired develop-
ment, innervation and function of pancreatic beta cell
mass and islet of Langerhans [42, 43]. Fetal malnutrition
exacerbates the risk of IR and obesity later in life in
cases of reversed (nutrient rich) environment and posi-
tive calorie balance due to increased food intake and de-
creased energy expenditure [44].
This increased susceptibility to NCD like DM due to
early life exposure and changes in adult lifestyles due to
globalisation is what is essentially seen in SSA.
Vitamin D deficiency which is caused by malnutrition
and other factors like chronic infections like TB, HIV
and dark skin pigmentation may also explain the in-
creased the odds of developing DM and the unique
manifestation in SSA [45]. Some of the integral roles of
vitamin D are increasing pancreatic beta cell production
of insulin by increasing intra-cellular calcium concentra-
tions, activation of intra cellular endopeptidases that
cleave pro-insulin to insulin and by preventing inflam-
matory damage of pancreatic beta cells [46].
Epigenetic modifications
Findings from both animal studies and recent large scale
human epigenome wide associated studies show epigen-
etics as the common link between genome and environ-
mental factors like chronic malnutrition and the
development of DM [47–49]. These could explain the
uniqueness in diabetes phenotypes in SSA.
According to the Developmental Origins of Health and
Disease fetal origins of adult disease hypothesis, in-utero
fetal programming induced by exposures to malnutrition,
stress and fetal infections like malaria and toxoplasmosis,
rubella, CMV, herpes simplex and syphilis (TORCHES)
results in short and long term adaptations which are partly
mediated by epigenetic changes. These adaptations are es-
sentially to ensure fetal survival [50].
Epigenetic changes ranging from DNA methylation,
histone modification and noncoding RNAs occur during
development, are transmitted from cell to cell (mitotic
inheritance) or generation to generation (transgenera-
tional epigenetic inheritance) and cause alteration of
gene expression, cellular growth, composition and physi-
ology [51].
These epigenetic changes result in simple organ failure
(reduction in cellular size and number), alteration in
endocrine systems (upregulation of the hypothalamic-pitui-
tary-adrenal axis and changes in secretion and sensitivity to
insulin and insulin-like growth factor-1) and changes in ex-
pression and regulation of DNA [52]. Epigenetic modifica-
tions that result in reduced pancreatic beta cell mass and
function coupled with changes in cellular insulin signaling,
reduced muscle mass and increased adiposity lead to an in-
creased likelihood of development of DM and could partly
explain the unique diabetes phenotype seen in SSA.
Changes or activation of the neuro-endocrine systems
Environmental insults such as maternal infection, stress
and malnutrition have been shown to activate the hypo-
thalamus pituitary adrenal axis with resultant increase in
the expression of the glucocorticoid receptors, dampen-
ing of the hypothalamic negative feedback mechanism
and increased production of stress hormones (glucocor-
ticoids) by the adrenal glands [53, 54].
Studies in rat models have demonstrated that high fetal
glucocorticoid levels due to stressful states or environ-
mental insults like malnutrition attenuate the expression
and activity of the placental enzyme 11β-hydroxysteroid
dehydrogenase type-2 that is key in modulating fetal ex-
posure to glucocorticoids [55, 56]. The downregulation of
this enzyme subsequently is associated with early onset of
glucose intolerance, hypertension and other cardiovascu-
lar diseases in adulthood.
Atypical forms of diabetes in Africa: Fibrocalculous
pancreatic diabetes and ketosis prone diabetes
The distinctiveness in the diabetes phenotype in SSA as
explained by the discussed factors above is further em-
phasized by the presence of these 2 unique atypical
forms of the diabetes i.e. KPD and fibrocalculous pan-
creatic diabetes (FCPD) which have been described par-
ticularly among patients of African ancestry [12, 14–18].
Despite being exclusively described in African popula-
tions, we lack population based studies in the region
investigating the prevalence of these atypical sub-types.
Ketosis prone diabetes (KPD)
Patients with KPD present with acute severe hypergly-
caemia and keto-acidosis but, in contrast to classic
T1DM lack pancreatic islet beta cell auto antibodies or a
genetic association with HLA [19]. The defects in pan-
creatic beta cell function and insulin sensitivity at pres-
entation in this condition remarkably improve with
insulin therapy, and many patients can discontinue insu-
lin following treatment of the acute episode, with near
normoglycaemic remission that may last from months to
years [19]. This insulin free period in patients with KPD
is similar to the well described “honeymoon period” seen
in patients with T2DM [57] and T1DM [58], which is a
drug free period with observed sustained optimal
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glycaemic control. This clinical observation is explained
by the resumption of endogenous insulin production by
the pancreatic beta cells after glucotoxicity is resolved
following acute intensive insulin therapy [59].
Fibrocalculous pancreatic diabetes (FCPD)
FCPD is one of the unique forms of malnutrition related
DM that develops secondary to non-alcoholic chronic
calcific pancreatitis and has been widely described in the
tropical developing countries in SSA [14, 18]. It is diag-
nosed mainly among young patients presenting with
abdominal pain, radiological confirmation of pancreatic
calcification and features of pancreatic exocrine (steator-
rhea) and endocrine (severe hyperglycaemia) insuffi-
ciency [60]. Patients with FCPD present with early
disease onset (< 30 years), an associated male preponder-
ance (70%), are underweight, of a low socio-economic
status and have severe hyperglycaemia that requires
insulin therapy in low doses to achieve euglycaemia [18,
60]. Diabetic keto-acidosis rarely develops following
insulin withdrawal because of partial preservation of
pancreatic beta cell function as evidenced by relatively
normal C-peptide levels, low glucagon levels and
decreased adipose tissue mass [60].
Discussion
The current paradigm shift in the classification of DM
underscores the need to understand the underlying
pathophysiologic mechanisms of hyperglycaemia be-
cause of their potential therapeutic implications [23].
Evidence based management of DM recommends the
use of combination therapy based on the defined under-
lying pathophysiological abnormalities or defects to
optimize management [23, 61].
From an African perspective, an in-depth understand-
ing of the underlying pathophysiologic defects and mani-
festation of DM offers important insights about the
optimal drug combinations or prevention strategies for
management and prevention of DM in this specific
patient population. These insights can also offer a plat-
form for future interventional studies to investigate
which pharmacotherapy (monotherapy or in combin-
ation) would be optimal in managing hyperglycaemia,
preservation of beta cell function or retarding progres-
sive beta cell failure in an African adult population with
DM, and may inform lifestyle advice and other strategies
to prevent or screen for diabetes.
Most clinicians in SSA manage their adult patients
with DM basing on guidelines developed by inter-
national diabetes associations like American Diabetes
Association [23]. These international guidelines are
developed based on evidence from phenotyping studies
of Caucasian or mixed ancestry populations, and may
therefore not be applicable and need to be cautiously ex-
trapolated to other populations.
An example is the recommendation to use metformin
as the first line therapy in the management of DM in
adult patients [23]. Metformin is currently the first
choice of therapy for T2DM in international guidelines
and it is the most commonly used first line therapy in
clinical practice in SSA. While there is clear evidence for
metformin being the optimal therapy in obese western
populations with T2DM, there is no evidence to show
this is the optimal first line treatment in African popula-
tions who have a completely different phenotype.
Conclusion
To address the paucity of clinical studies describing the
diabetic phenotype of native African patients, more large
studies comprehensively assessing the clinical and meta-
bolic profile of adult patients especially among newly
diagnosed patients with DM are warranted to further
improve the understanding of the manifestation of DM
in SSA. This will be key in informing the formulation of
optimal therapeutic options and targeted preventive
strategies for DM that are individualised for the African
population.
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